Global Pulmonary Arterial Hypertension Market (2017 to 2030) - Insights, Epidemiology and Market Forecast - ResearchAndMarkets.com - Yahoo Finance
Global Pulmonary Arterial Hypertension Market (2017 to 2030) - Insights, Epidemiology and Market Forecast - ResearchAndMarkets.com - Yahoo Finance |
| Posted: 08 Apr 2020 12:00 AM PDT   The "Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH's in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Key Benefits
Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction. The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the PAH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe and Japan. Pulmonary Arterial Hypertension Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030. According to the publisher, the total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017. Key Topics Covered: 1. Key Insights 2. Executive Summary of Pulmonary Arterial Hypertension 3. SWOT Analysis for Pulmonary Arterial Hypertension 4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance 4.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017 4.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030 5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH) 5.1. Introduction 5.2. Signs and Symptoms 5.3. Classification of Pulmonary Arterial Hypertension (PAH) 5.3.1. WHO classification 5.3.2. Functional Classification of PAH 5.4. Etiology 5.5. Risk factors 5.6. Pathophysiology 5.7. Diagnosis 5.7.1. Diagnostic Guidelines: European Guidelines of PAH 6. Epidemiology and Patient Population 6.1. Key Findings 6.2. Population and Forecast Parameters 6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH] 7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH) 7.1. The United States 7.2. Germany 7.3. France 7.4. Italy 7.5. Spain 7.6. The United Kingdom 7.7. Japan 8. Treatment Algorithm 8.1. Current Treatment Practices 8.2. Treatment Guidelines 8.2.1. CHEST Guidelines [The United States] 8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines 9. Unmet Needs 10. Case Studies 10.1. A Rare Case of Drug Induced PAH 10.2. A Case Report of Unconventional Delivery of Inhaled NO 11. Organizations related with PAH 12. Marketed Drugs 12.1. Approval and Market Presence 13. Marketed Drugs by Companies 13.1. United Therapeutics Corporation 13.2. Johnson & Johnson 13.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc. 13.4. Bayer AG 13.5. Pfizer 14. Safety and Efficacy of Marketed Drugs 15. Emerging Therapies 15.1. Emerging Drugs Analysis 15.2. Aurora-GT: United Therapeutics 15.3. Ralinepag: United Therapeutics 15.4. Liquidia Technologies 15.5. Bardoxolone Methyl: Reata Pharmaceuticals 15.6. Rodatristat Ethyl: Altavant Sciences 15.7. Sotatercept: Acceleron Pharma 15.8. PB1064: PhaseBio Pharmaceuticals 15.9. CXA-10: Complexa 16. Other Promising Candidates 16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies 16.2. RT234: Respira Therapeutics 17. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis 17.1. Key Findings 17.2. Total Market Size of PAH in 7MM 17.3. Market Outlook: 7MM Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/uwmsvd View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005617/en/ Contacts ResearchAndMarkets.com For E.S.T Office Hours Call 1-917-300-0470  |
| You are subscribed to email updates from "pulmonary hypertension diagnosis" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment